跳至主要内容
临床试验/NL-OMON56433
NL-OMON56433招募中不适用

Deuterium Metabolic MRI and [18F]-flourodesoxyglucose Positron Emission Tomography for Assessment of Treatment Response Following Radioembolization of Liver Metastasis; pilot study, - DEPLETE

niversitair Medisch Centrum Utrecht0 个研究点目标入组 15 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
15

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Adults (>=18 years)
  • - Referred for SIRT and deemed eligible by the multidisciplinary tumor board
  • - Size of at least one liver metastasis >= 1 cm on contrast enhanced CT / MRI
  • (measurable according to RECIST 1.1) and 18FDG-avid metastatic liver disease
  • (uptake > healthy liver uptake; measurable according to PERCIST)
  • - Written informed consent

排除标准

  • - Patients having FDG-negative disease (according to PERCIST)
  • - Patients with diabetes mellitus
  • - Patients having a general contra-indication for SIRT
  • - Patients with contra-indications for 7T MR scanning
  • - Patient unable to complete study scan (laying still for a long time)
  • - Patient unable or incapable to follow study proceedings

研究者

发起方
niversitair Medisch Centrum Utrecht

相似试验